Results 41 to 50 of about 22,433 (204)

Naltrexone ameliorates functional network abnormalities in alcohol dependent individuals [PDF]

, 2017
Naltrexone, an opioid receptor antagonist, is commonly used as a relapse prevention medication in alcohol and opiate addiction but its efficacy and the mechanisms underpinning its clinical usefulness are not well characterised.
Suckling, John, Taylor, E.M, Morris, LS, Csaba Orban, Taylor, EM, Valerie Voon, Bill Deakin, Deakin, B, Eleanor M. Taylor, Lingford-Hughes, Anne R., Deakin, Bill, McGonigle, J, Sahakian, B.J, Passetti, F, Sahakian, BJ, Elliott, Rebecca, Rebecca Elliott, John Suckling, Morris, L.S, Robbins, T.W, Ersche, K.D, Dana Smith, Nutt, DJ, Suckling, J, Smith, Dana, Robbins, Trevor W., Flechais, Remy, Paterson, LM, Nestor, Liam J., Bullmore, ET, David J. Nutt, Lingford-Hughes, A.R, Roger Tait, Reed, L, Flechais, R, Morris, Laurel S, null null, Voon, Valerie, Tait, Roger, McGonigle, John, Orban, Csaba, Sahakian, Barbara J., Kwangyeol Baek, Rabiner, I, ICCAM Consortium, Murphy, A, Smith, D, Louise M. Paterson, Baek, Kwangyeol, Laurence Reed, Elliott, R, Remy Flechais, Passetti, Filippo, Karen D. Ersche, Nestor, LJ, Baek, K, Trevor W. Robbins, Paterson, L.M, Bullmore, Edward T., Murphy, Anna, Liam J. Nestor, Rabiner, Ilan, Anna Murphy, Laurel S. Morris, Robbins, TW, Orban, C, Barbara J. Sahakian, John McGonigle, Nutt, D.J, Tait, R, Taylor, Eleanor M., ICCAM Consorti, Reed, Laurence, Nutt, David J., Edward T. Bullmore, Lingford-Hughes, AR, Ilan Rabiner, Ersche, Karen D., Ersche, KD, Anne R. Lingford-Hughes, Voon, V, Paterson, Louise M., Filippo Passetti, Morris, Laurel S., Nestor, L.J, Bullmore, E.T   +85 more
core   +2 more sources

Naltrexone Induced Serotonin Syndrome [PDF]

, 2013
Background: Serotonin syndrome resulted from hyperactivity of serotonin in nervous system and is potentially life threatening. Tramadol is known as one it's causing factors.
Behnoush, B, Memarian, A, Teimoory, M
core   +1 more source

The association between naloxone distribution, buprenorphine treatment and retention and incident high‐risk opioid prescribing with opioid overdose death in Kentucky, Massachusetts, New York and Ohio, United States: An exploratory community‐level cohort study of data from the HEALing Communities Study

Addiction, EarlyView.
Abstract Aim We evaluated whether community‐level naloxone distribution, medication for opioid use disorder treatment and retention and incident high‐risk opioid prescribing rates were associated with opioid overdose death rates. Design Observational cohort conducted using 2019 to 2023 community‐level data as an exploratory analysis of the HEALing ...
Alexander Y. Walley, Debbie M. Cheng, Nathan Vandergrift, Marc Larochelle, JaNae Holloway, Jennifer L. Brown, Redonna Chandler, Laura C. Fanucchi, Daniel J. Feaster, Patricia R. Freeman, Timothy Hunt, Michelle R. Lofwall, Hannah K. Knudsen, Edward V. Nunes, Emmanuel Oga, Douglas R. Oyler, Jeffrey H. Samet, Jennifer Villani, Sharon L. Walsh, T. John Winhusen   +19 more
wiley   +1 more source

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives

, 2016
Cenk Tek Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Abstract: Naltrexone, an opiate antagonist, and bupropion, a noradrenergic/dopaminergic antidepressant, have many effects on the reward systems of the brain.
Tek C
core  

Naltrexone Reverses Ethanol Preference and Protein Kinase C Activation in Drosophila melanogaster [PDF]

Alcohol use disorder (AUD) is a major health, social and economic problem forwhich there are few effective treatments. The opiate antagonist naltrexone is currently prescribed clinically with mixed success.
Ayoub, Samir, Corcoran, Olivia, Casalotti, Stefano, Jonaitis, Julius, Latchooman, Nilesh, Koyyada, Rajeswari   +5 more
core   +1 more source

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

Achieving long-term continuous blood naltrexone and 6-β-naltrexol coverage following sequential naltrexone implants

, 2004
The aim of this study was to assess blood free naltrexone and 6-β-naltrexol levels with time following treatment with sequential sustained-release naltrexone preparations. Data were collected from blood samples analysed independently for naltrexone and 6-
Hansson, Robert C, Hulse, Gary K, Chan, C-T, Arnold-Reed, Diane, O\u27Neil, George, O\u27Neil, P   +5 more
core   +1 more source

Factors associated with readmission to residential treatment among clients transitioned from detoxification services in Alberta, Canada

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Readmission to residential treatment increases healthcare costs, strains publicly funded systems, and may not adequately meet clients' needs. This study examined rates and predictors of readmission to residential treatment among clients transitioned from detoxification services.
Abreham Mekonnen
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

, 2015
Anna M Buehler Hospital Alemao Oswaldo Cruz, Institute of Health Education and Sciences, Sao Paulo, BrazilI read with great interest the systematic review by Caixàs et al1 on the effect of naltrexone sustained-release/bupropion sustained-release (
Buehler AM
core